Sitagliptin linked to lower mortality rate in adults with type 2 diabetes, COVID-19

Adults with type 2 diabetes who were hospitalized with COVID-19 in northern Italy had a lower mortality rate and better health outcomes when treated with the DPP-IV inhibitor sitagliptin, according to study data published in Diabetes Care.“Type 2 diabetes increases the mortality risk in patients with COVID-19, particularly in those with more severe disease,” Sebastiano Bruno Solerte,

Read the full article here

Related Articles